Ferowsi Pecoraro is a pharmacist who is specialized in Oncology in Tacoma, Washington. Patients can reach her at 1708 Yakima Ave, Suite 203, Tacoma or contact her on 253-382-8150. Active license number of Ferowsi Pecoraro is PH00040086 for Oncology in Washington. Ferowsi Pecoraro is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Ferowsi Pecoraro speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Ferowsi Pecoraro
Specialization:
Oncology
Gender:
Female
Location:
1708 Yakima Ave, Suite 203, Tacoma, Washington, 98405-5307
Phone:
253-382-8150
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Ferowsi Pecoraro are as mentioned below.
NPI Number:
1427500867
NPI Enumeration Date:
02 Nov, 2016
NPI Last Update On:
02 Nov, 2016
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Ferowsi Pecoraro are as mentioned below.
Specialization
License Number
State
Status
Oncology
PH00040086
Washington
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1708 Yakima Ave, Suite 203 Tacoma, Washington
Zip:
98405-5307
Phone Number:
253-382-8150
Fax Number:
--
Patients can reach Ferowsi Pecoraro at 1708 Yakima Ave, Suite 203, Tacoma, Washington or can call on phone at 253-382-8150.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.